AIM:N4P

Stock Analysis Report

Executive Summary

N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • N4 Pharma has significant price volatility in the past 3 months.
  • N4 Pharma is not covered by any analysts.

Share Price & News

How has N4 Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

16.9%

N4P

3.9%

GB Pharmaceuticals

-0.2%

GB Market


1 Year Return

-10.5%

N4P

21.5%

GB Pharmaceuticals

-1.9%

GB Market

N4P underperformed the Pharmaceuticals industry which returned 21.5% over the past year.

N4P underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -1.8% over the past year.


Share holder returns

N4PIndustryMarket
7 Day16.9%3.9%-0.2%
30 Day16.9%-1.8%4.4%
90 Day-11.6%9.9%0.5%
1 Year-10.5%-10.5%25.1%21.5%2.9%-1.9%
3 Yearn/a45.5%31.5%20.7%6.3%
5 Yearn/a91.2%59.9%33.2%5.1%

Price Volatility Vs. Market

How volatile is N4 Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is N4 Pharma undervalued based on future cash flows and its price relative to the stock market?

2.77x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for N4 Pharma to establish if it is available at moderate discount.

Unable to calculate intrinsic value for N4 Pharma to establish if it is available at substantial discount.


Price Based on Earnings

N4 Pharma is loss making, we can't compare its value to the GB Pharmaceuticals industry average.

N4 Pharma is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for N4 Pharma, we can't assess if its growth is good value.


Price Based on Value of Assets

N4 Pharma is overvalued based on assets compared to the GB Pharmaceuticals industry average.


Next Steps

Future Growth

How is N4 Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as N4 Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has N4 Pharma performed over the past 5 years?

-1977.4%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

N4 Pharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare N4 Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare N4 Pharma's 1-year growth to the GB Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if N4 Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if N4 Pharma has efficiently used its assets last year compared to the GB Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if N4 Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is N4 Pharma's financial position?


Financial Position Analysis

N4 Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

N4 Pharma has no long term commitments.


Debt to Equity History and Analysis

N4 Pharma has no debt.

N4 Pharma currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

N4 Pharma has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

N4 Pharma has less than a year of cash runway based on current free cash flow.

N4 Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 47.4% each year.


Next Steps

Dividend

What is N4 Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate N4 Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate N4 Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as N4 Pharma has not reported any payouts.

Unable to verify if N4 Pharma's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as N4 Pharma has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of N4 Pharma's salary, the management and board of directors tenure and is there insider trading?

0.7yrs

Average management tenure


CEO

Nigel Theobald (55yo)

2.3yrs

Tenure

0

Mr. Nigel James Theobald has been Chief Executive Officer of N4 Pharma Plc since May 3, 2017 and serves as its Director. Mr. Theobald served as the Head of Emerge Marketing Ltd., for Alltracel Pharmaceutic ...


Management Age and Tenure

0.7yrs

Average Tenure

The average tenure for the N4 Pharma management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.3yrs

Average Tenure

53yo

Average Age

The average tenure for the N4 Pharma board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUK£5,98010 Apr 19
Nigel Theobald
EntityIndividual
Role
Chief Executive Officer
Founder
Shares134,686
Max PriceUK£0.044

Ownership Breakdown


Management Team

  • Nigel Theobald (55yo)

    Founder

    • Tenure: 2.3yrs
  • Andrew Leishman

    Consultant

    • Tenure: 0.7yrs
  • David Templeton

    Part-Time Executive Director & Technical Director

    • Tenure: 2.3yrs

Board Members

  • John Chiplin (60yo)

    Non-Executive Chairman

    • Tenure: 0.3yrs
  • Nigel Theobald (55yo)

    Founder

    • Tenure: 2.3yrs
  • Luke Cairns (41yo)

    Independent Non-Executive Director

    • Tenure: 0yrs
  • David Templeton

    Part-Time Executive Director & Technical Director

    • Tenure: 2.3yrs
  • Chris Britten (51yo)

    Non-Executive Director

    • Tenure: 0.3yrs

Company Information

N4 Pharma Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: N4 Pharma Plc
  • Ticker: N4P
  • Exchange: AIM
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£3.678m
  • Shares outstanding: 101.46m
  • Website: https://www.n4pharma.com

Number of Employees


Location

  • N4 Pharma Plc
  • 60 Gracechurch Street
  • 6th Floor
  • London
  • Greater London
  • EC3V 0HR
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
N4PAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMay 2017

Biography

N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 21:42
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.